Kateřina Kubáčková

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo et al. · The Lancet Oncology · 2015 · 845 citations · Full text

Medicine, Oncology, Pharmacology +9

Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer

Michal Podrazil, Rudolf Horváth, Étienne Becht et al. · Oncotarget · 2015 · 136 citations · Full text

Medicine, Immunology, Oncology +17

Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas

Miluse Hubackova, Radka Václavíková, Marie Ehrlichová et al. · International Journal of Cancer · 2011 · 60 citations · Full text

Medicine, Molecular Genetics, Oncology +15

Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement

Eduard Vrdoljak, G. Bodoky, Jacek Jassem et al. · The Oncologist · 2016 · 51 citations · Full text

Medicine, Health Policy, Oncology +17

Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs

Blanka Řı́hová, J. Strohalm, Kateřina Kubáčková et al. · Journal of Controlled Release · 2002 · 48 citations

Medicine, Immunology, Pharmacology +14